Ilsan Hospital   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Goyang Korea, Republic of (2000)

Organization Overview

First Clinical Trial
2008
NCT00698607
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Health Insurance Service Ilsan Hospital | Ilsan-Paik Hospital | National Health Insurance Service Ilsan Hospital | NHIC Ilsan hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Adenomyosis (Phase 3)

Alzheimer Disease (Phase 2)

Anemia (Phase 4)

Coronary Artery Disease (Phase 4)

Essential Hypertension (Phase 3)

Glomerulonephritis (Phase 3)

Hepatitis (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hypertension (Phase 3)

Intermittent Claudication (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Leiomyoma (Phase 3)

Myofibroma (Phase 3)

Nausea (Phase 3)

Neuralgia (Phase 4)

Ovarian Neoplasms (Phase 3)

Peripheral Arterial Disease (Phase 2)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Spinal Cord Injuries (Phase 4)

Ureteral Calculi (Phase 4)

Ureterolithiasis (Phase 4)

Vomiting (Phase 3)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 22